Ann M Denadai, PTA | |
2250 Hickory Rd, Ste 240, Plymouth Meeting, PA 19462 | |
(610) 834-1122 | |
Not Available |
Full Name | Ann M Denadai |
---|---|
Gender | Female |
Speciality | Physical Medicine & Rehabilitation |
Location | 2250 Hickory Rd, Plymouth Meeting, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669673711 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | TE001422L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ann M Denadai, PTA 214 Walnut Hill Rd, West Chester, PA 19382 Ph: (610) 324-0535 | Ann M Denadai, PTA 2250 Hickory Rd, Ste 240, Plymouth Meeting, PA 19462 Ph: (610) 834-1122 |
News Archive
Leaders of the 1000 Genomes Project announced today that three firms that have pioneered development of new sequencing technologies have joined the international effort to build the most detailed map to date of human genetic variation as a tool for medical research. The new participants are: 454 Life Sciences, a Roche company, Branford, Conn.; Applied Biosystems, an Applera Corp. business, Foster City, Calif.; and Illumina Inc., San Diego.
Loyola Medicine is among the first centers to offer a new minimally invasive prostate biopsy that minimizes the risk of infection and may increase the cancer detection rate.
Simulations Plus, Inc., a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced today the release of Version 8.0 of its flagship GastroPlus simulation software with significantly expanded functionality and user convenience.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes.
› Verified 4 days ago
Michael Cheikin, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 832 Germantown Avenue, Suite 3, Plymouth Meeting, PA 19462 Phone: 610-239-9901 Fax: 866-217-0158 | |
Michelle M. Chesla, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2250 Hickory Rd, Suite 240, Plymouth Meeting, PA 19462 Phone: 610-834-1122 |